title: High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.
abstract: Thirty-two patients with metastatic carcinoma of the prostate refractory to endocrine therapy were entered on trial. No patient entered in the study had prior chemotherapy. Patients were treated with 5-fluorouracil given at a dosage of 4 gm/m2 over a 24-hour period every 2 weeks. Of the 27 patients evaluable for response, there were no complete or partial remissions, but 9 (33%) had a stable disease. The 95% confidence interval for complete and partial response in this series (0 of 27 patients) is 0.0-12%. Myelosuppression and gastrointestinal toxicity was moderate. Two patients, however, experienced major but completely reversible neurotoxicity, including 1 with cerebellar ataxia and 1 with memory loss and stroke-like symptoms. These data indicate that high-dose fluorouracil used in this dosage and schedule is ineffective in the therapy of advanced carcinoma of the prostate.
authors.affiliation: Cancer Center, Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, NC 27103.
authors.forename: J N
authors.initials: JN
authors.lastname: Atkins
authors.forename: H B
authors.initials: HB
authors.lastname: Muss
authors.forename: D
authors.initials: D
authors.lastname: Case
authors.forename: J
authors.initials: J
authors.lastname: Brockschmidt
authors.forename: F M
authors.initials: FM
authors.lastname: Schnell
authors.forename: M
authors.initials: M
authors.lastname: O'Rourke
authors.forename: T H
authors.initials: TH
authors.lastname: Grote
authors.forename: J H
authors.initials: JH
authors.lastname: West
authors.forename: S
authors.initials: S
authors.lastname: Anthony
authors.forename: V
authors.initials: V
authors.lastname: Stanley
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D005472:Fluorouracil